Skip to main content

Table 3 EC50 fold-changes on resistant viruses

From: Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage

Compound

EC50(μM)

EC50fold change

NL4-3 WT

PI

NRTIs

Multi-drug*

NNRTIs

INSTIs

RAL

0.007

1

1

0.5

1

374

EVG

0.003

1

0.3

0.3

1

2036

AZT

0.14

1

88

10

0.1

0.4

NVP

0.16

1

3

14

287

1

IDV

0.032

9

1

1

1

1

Mut101

0.47

1

1

1

1

1

  1. EC50 fold change (FC) of Mut101, Raltegravir (RAL), Elvitegravir (EVG), Nevirapine (NVP), Zidovudine (AZT) and Indinavir (IDV) (ratio of the EC50 on resistant viruses to the EC50 on the wt virus). Data represent the mean of two independent experiments. * contains resistance mutations against NRTIs and NNRTIs.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us